Investment Thesis
Nektar Therapeutics is in severe financial distress with collapsing revenue (-43.9% YoY), unsustainable cash burn (-$208.7M FCF), and critically depleted liquidity ($15.1M cash against -$208.5M operating cash outflow). The company will exhaust cash reserves within weeks at current burn rates, creating imminent refinancing risk with a leveraged balance sheet (1.49x debt/equity).
Strengths
- Adequate current ratio of 4.97x provides near-term liquidity buffer
- Company retains $55.2M in quarterly revenue from existing operations
- Total equity of $89.8M provides some balance sheet cushion
Risks
- Critical liquidity crisis: $15.1M cash against -$208.5M quarterly operating cash burn
- Revenue collapse of 43.9% YoY indicates fundamental demand weakness for products
- Extreme operating losses (-253.7% margin) with near-zero gross margins (1.1%) suggests core business unprofitability
- High debt burden ($133.5M) limits refinancing options and may trigger covenants
- Negative free cash flow of -$208.7M is unsustainable; refinancing risk is acute
Key Metrics to Watch
- Cash position and burn rate trajectory - solvency indicator
- Revenue stabilization and YoY growth trend - business viability
- Debt covenant compliance and refinancing announcements - bankruptcy risk
- Gross margin improvement - product profitability
Financial Metrics
Revenue
55.2M
Net Income
-164.1M
EPS (Diluted)
$-9.73
Free Cash Flow
-208.7M
Total Assets
280.4M
Cash
15.1M
Profitability Ratios
Gross Margin
1.1%
Operating Margin
-253.7%
Net Margin
-297.1%
ROE
-182.6%
ROA
-58.5%
FCF Margin
-377.8%
Balance Sheet & Liquidity
Current Ratio
4.97x
Quick Ratio
4.97x
Debt/Equity
1.49x
Debt/Assets
68.0%
Interest Coverage
N/A
Long-term Debt
133.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T07:21:22.829979 |
Data as of: 2025-12-31 |
Powered by Claude AI